Radiopharm Theranostics Limited
Cash Flow Statement
| Line Item | FY2025 | FY2024 | FY2023 |
|---|---|---|---|
| Operating Activities | |||
| Net Income | $-38.3M | $-47.9M | $-34.6M |
| Depreciation & Amortization | — | — | — |
| Depreciation | — | — | — |
| Amortization | $15.7M | $13.1M | — |
| Stock-Based Compensation | — | — | — |
| Net Cash from Operating Activities | $-36.6M | $-23.0M | $-23.2M |
| Investing Activities | |||
| Capital Expenditures | — | — | $45.3K |
| Business Acquisitions | — | — | — |
| Net Cash from Investing Activities | $1.8M | $-320.0K | $-1.5M |
| Financing Activities | |||
| Dividends Paid | — | — | — |
| Stock Repurchases | — | — | — |
| Net Cash from Financing Activities | $45.4M | $30.2M | $9.2M |
| Net Change in Cash | — | — | — |
| Free Cash Flow | — | — | $-23.2M |